Spring brings warmer weather, but for allergy sufferers, it also means sneezing, wheezing and itchy eyes. Instead of ...

Results from a Phase III study in pediatric patients demonstrated that Odactra reduced the total combined rhinitis score by 22% compared to placebo.

Taken as a once-daily tablet, the SLIT product is now indicated for treating dust mite-related allergic rhinitis, with or ...

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s ...

The global allergy immunotherapy market is poised for significant growth, projected to expand from USD 1.94 billion in 2025 ...

With over half the cells in the human body being bacterial rather than human, and over 99% of the genes in the human body ...

The time of day of immunotherapy infusions does appear to affect patient outcomes. But convincing the wider oncology ...

An experimental treatment for an aggressive and lethal brain cancer has been published in Nature Medicine, paving the way for ...

The Food and Drug Administration (FDA) has expanded the approval of Odactra® (house dust mite allergen tablet) to include the treatment of house dust mite ...

New findings could help make immunotherapies for brain cancer more effective. The team analyzed almost 200,000 individual immune cells in tumor samples taken from patients with glioma, the most common ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

Researchers identify predictive markers of response to immunotherapy treatment in a study involving data from over 700 patients across six different cohorts. The study has significant relevance, ...